Published in
Elsevier, Transplantation and Cellular Therapy, 11(28), p. 750.e1-750.e6, 2022
DOI: 10.1016/j.jtct.2022.08.010
Links
Tools
The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial
Journal article published in 2022 by
Miguel-Angel Perales 
,
John Kuruvilla,
Julia Thornton Snider,
Sachin Vadgama ,
Rob Blissett,
Fadoua El-Moustaid ,
Nathaniel J. Smith,
Anik R. Patel,
Patrick B. Johnston
,
John Kuruvilla,
Julia Thornton Snider,
Sachin Vadgama ,
Rob Blissett,
Fadoua El-Moustaid ,
Nathaniel J. Smith,
Anik R. Patel,
Patrick B. Johnston
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 